title: Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares.
abstract: Recurrent hepatitis and acute rejection share common features which make difficult for diagnosis in liver transplant hepatitis C virus (HCV) positive patients. We studied the usefulness of quantitative monitoring of HCV RNA and immunoglobulin (Ig)M anti-HCV in the differential diagnosis between recurrent hepatitis and acute rejection in 98 consecutive anti-HCV positive liver transplant patients. Aminotransferase levels, serum HCV RNA and IgM anti-HCV were measured at the time of transplantation and monthly thereafter. A liver biopsy (LB) was obtained when serum aminotransferase levels increased to twice or more than normal. During a mean follow-up of 16 months 86 aminotransferase flares were observed. Histology was compatible with recurrent hepatitis C in 44 cases and with acute rejection in 28, doubtful in 14. The fluctuations of HCV RNA serum levels were not significantly different in the three groups. Serum IgM anti-HCV levels increased (from negative to positive or with value variations > or = 0.18) in 36 of 44 cases with recurrent hepatitis C at the time of alanine aminotransferase (ALT) flare. IgM anti-HCV remained unchanged in all rejection cases (P < 0.001), but increased in 10 of 11 histologically doubtful cases that were diagnosed as hepatitis at the second LB. Increasing serum levels of IgM anti-HCV at the time of ALT flares are significantly associated with recurrent hepatitis C in liver transplant patients. The quantitative monitoring of IgM anti-HCV appears to be an additional diagnostic tool for distinguishing recurrent hepatitis C from acute graft rejection with a 100% specificity; 100% positive predictive value and 88.9% diagnostic accuracy.
authors.affiliation: U.O. Gastroenterologia e Epatologia, Azienda Ospedaliera Pisana e Università di Pisa, via Paradisa 2, Ospedale Cisanello, 56124 Pisa, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Ciccorossi
authors.forename: F
authors.initials: F
authors.lastname: Filipponi
authors.forename: F
authors.initials: F
authors.lastname: Oliveri
authors.forename: D
authors.initials: D
authors.lastname: Campani
authors.forename: P
authors.initials: P
authors.lastname: Colombatto
authors.forename: F
authors.initials: F
authors.lastname: Bonino
authors.forename: M
authors.initials: M
authors.lastname: Campa
authors.forename: G
authors.initials: G
authors.lastname: Maltinti
authors.forename: F
authors.initials: F
authors.lastname: Mosca
authors.forename: M R
authors.initials: MR
authors.lastname: Brunetto
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000378:metabolism; D051263:D-Alanine Transaminase; D005260:Female; D006084:Graft Rejection; D016174:Hepacivirus / Q000276:immunology*; D006526:Hepatitis C / Q000175:diagnosis* / Q000276:immunology; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D012680:Sensitivity and Specificity
chemical_list: D018937:Hepatitis C Antibodies; D007075:Immunoglobulin M; D012367:RNA, Viral; D000410:Alanine Transaminase; D051263:D-Alanine Transaminase